Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens

Histopathology

Volumn 54, Issue 2, 2009, Pages 248-253

  Shousha, S ^a,b   Peston, D ^b   Amo Takyi, B ^b   Morgan, M ^c   Jasani, B ^c  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

Breast carcinoma; Core biopsies; FISH; HER2; SISH

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER SURGERY; CHROMOSOME 17; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; ONCOGENE NEU; PRIORITY JOURNAL; SCORING SYSTEM; SILVER ENCHANCED IN SITU HYBRIDIZATION; TUMOR BIOPSY;

AUTOMATION; BIOPSY, NEEDLE; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RECEPTOR, ERBB-2; SILVER STAINING;

EID: 58649120081     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03185.x     Document Type: Article

References (14)

1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2- positive breast cancer. New Engl. J. Med. 2005 353 1659 1672.
2. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer. New Engl. J. Med. 2005 353 1673 1684.
3. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 369 29 36.
4. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl. J. Med. 2006 355 2733 2743.
5. Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou J-Y. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin. Cancer Res. 2005 11 6598 6607.
6. Lewis F, Jackson P, Lane S, Coast G, Hanby AM. Testing for HER2 in breast cancer. Histopathology 2004 45 207 217.
7. Dietel M, Ellis IO, Hofler H et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007 451 19 25.
8. Arnould L, Arveux P, Couturier J et al. Pathologic complete response to Trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin. Cancer Res. 2007 13 6404 6409.
9. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol. 1999 17 1983 1987.
10. Hammock L, Lewis M, Phillips C, Cohen C. StrongHER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum. Pathol. 2003 34 1043 1047.
11. Rossi E, Ubiali A, Cadei M et al. Her-2/neu in breast cancer. A comparative study between histology, immunohistochemistry, and molecular technique (FISH). Appl. Immunohistochem. Mol. Morphol. 2006 14 127 131.
12. Dowsett M, Hanna WM, Kockx M et al. Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod. Pathol. 2007 20 584 591.
13. Wolff AC, Hammond EH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007 25 118 145.
14. Walker R, Bartlett J, Dowsett M et al. HER2 testing in the UK - further update to recommendations. J. Clin. Pathol. 2008 61 818 824.